drugset / Trial / NCT06001567
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
NaSingle-groupOpen-labelTreatment
Summary
This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion chemotherapy (HAIC).
Timeline
- Start
- 2023-08-14
- Primary completion
- 2024-08-13
- Completion
- 2024-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 40 mg | Oral |
| Subject | Avatrombopag | Small molecule | 60 mg | Oral |